

Clinical Pharmacogenetics Implementation Consortium
Pharmacogeneticsâ€™ Guided Warfarin Dosing: 2017 Upd

Clinical Pharmacology and Therapeutics

102, 397-404

DOI: 10.1002/cpt.668

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting. <i>Physiological Genomics</i> , 2017, 49, 346-354.	1.0	8
2	Time to revisit warfarin pharmacogenetics. <i>Future Cardiology</i> , 2017, 13, 511-513.	0.5	8
3	Pharmacogenomic Testing and Warfarin. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1110.	3.8	13
4	Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai. <i>Pharmacogenomics</i> , 2017, 18, 1381-1386.	0.6	20
5	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1115.	3.8	198
6	Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 267-272.	1.0	16
7	Warfarin Pharmacogenomics in Diverse Populations. <i>Pharmacotherapy</i> , 2017, 37, 1150-1163.	1.2	77
8	Interview about the GIFT Trial, Pharmacogenetics, and Warfarin. <i>Pharmacogenomics</i> , 2017, 18, 1379-1380.	0.6	1
9	Next-Generation Sequencing in Diagnostic Pathology. <i>Pathobiology</i> , 2017, 84, 292-305.	1.9	33
10	Influence of common and rare genetic variation on warfarin dose among African-American and European-American using the exome array. <i>Pharmacogenomics</i> , 2017, 18, 1059-1073.	0.6	12
11	Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement. <i>Pharmacogenomics</i> , 2017, 18, 1051-1057.	0.6	6
12	Genetic variation in human drug-related genes. <i>Genome Medicine</i> , 2017, 9, 117.	3.6	104
13	Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 347.	1.6	18
14	Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. <i>Journal of Personalized Medicine</i> , 2017, 7, 14.	1.1	29
15	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. <i>Journal of Personalized Medicine</i> , 2017, 7, 20.	1.1	12
16	Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. <i>Critical Care</i> , 2017, 21, 257.	2.5	105
17	Pharmacogenetic Information in Clinical Guidelines: The European Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 795-801.	2.3	71
18	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. <i>Clinical Cardiology</i> , 2018, 41, 576-585.	0.7	19

#	ARTICLE	IF	CITATIONS
19	Genetic Testing in Clinical Settings. American Journal of Kidney Diseases, 2018, 72, 569-581.	2.1	33
20	Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists. American Journal of Cardiology, 2018, 121, 879-887.	0.7	13
21	Clinical Review of the Pharmacogenomics of Direct Oral Anticoagulants. Cardiovascular Drugs and Therapy, 2018, 32, 121-126.	1.3	16
22	Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population. Pharmacotherapy, 2018, 38, 205-216.	1.2	21
23	Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population. Cardiovascular Therapeutics, 2018, 36, e12315.	1.1	7
24	Genotype-guided warfarin therapy: current status. Pharmacogenomics, 2018, 19, 667-685.	0.6	38
25	PRECISION MEDICINE: FROM DILOTYPES TO DISPARITIES TOWARDS IMPROVED HEALTH AND THERAPIES. , 2018, , .		3
26	The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 640-646.	0.7	2
27	Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clinical Pharmacology and Therapeutics, 2018, 103, 599-618.	2.3	186
28	An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports, 2018, 9, 10-11.	1.5	82
29	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genetics in Medicine, 2018, 20, 622-629.	1.1	66
30	Biomarkers of adverse drug reactions. Experimental Biology and Medicine, 2018, 243, 291-299.	1.1	25
31	Precision medicine: does ethnicity information complement genotype-based prescribing decisions?. Therapeutic Advances in Drug Safety, 2018, 9, 45-62.	1.0	58
32	VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. Future Cardiology, 2018, 14, 15-26.	0.5	4
33	Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. Experimental Biology and Medicine, 2018, 243, 313-322.	1.1	13
34	Structural Destabilization of Intramolecular Duplexes Improves the Results of DNA Hybridization Analysis. Biophysics (Russian Federation), 2018, 63, 880-887.	0.2	0
35	“WarfarinSeer” a predictive tool based on SMOTE-random forest to improve warfarin dose prediction in Chinese patients. , 2018, , .		6
36	Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 169-178.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	1
38	A scientist engineer's contribution to therapeutic discovery and development. <i>Experimental Biology and Medicine</i> , 2018, 243, 1125-1132.	1.1	1
39	Pharmacogenetics of warfarin dosing in patients of African and European ancestry. <i>Pharmacogenomics</i> , 2018, 19, 1357-1371.	0.6	28
40	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <i>Advances in Molecular Pathology</i> , 2018, 1, 125-134.	0.2	5
41	Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens. , 2018, , 169-202.		4
42	Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. <i>Frontiers in Pharmacology</i> , 2018, 9, 1436.	1.6	12
43	Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS). <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 258-263.	1.1	9
44	Microfluidic approaches for cell-based molecular diagnosis. <i>Biomicrofluidics</i> , 2018, 12, 051501.	1.2	6
45	Clinical Pharmacogenomics. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1561-1571.	2.2	18
46	Cytochrome P450 in Pharmacogenetics: An Update. <i>Advances in Pharmacology</i> , 2018, 83, 3-32.	1.2	113
47	Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1555-1566.	0.8	6
48	Value of VKORC1 (rs1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population. <i>Indian Heart Journal</i> , 2018, 70, S110-S115.	0.2	5
49	P450 Pharmacogenetics in Indigenous North American Populations. <i>Journal of Personalized Medicine</i> , 2018, 8, 9.	1.1	22
50	Warfarin: The End or the End of One Size Fits All Therapy?. <i>Journal of Personalized Medicine</i> , 2018, 8, 22.	1.1	26
51	Patient Care Situations Benefiting from Pharmacogenomic Testing. <i>Current Genetic Medicine Reports</i> , 2018, 6, 43-51.	1.9	1
52	Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. <i>Blood</i> , 2018, 132, 1974-1984.	0.6	24
53	Cytochrome P450 genotype-guided drug therapies: An update on current states. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 991-1001.	0.9	19
54	Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: lessons from warfarin. <i>Pharmacogenomics</i> , 2018, 19, 875-881.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Population Diversity in Pharmacogenetics: A Latin American Perspective. <i>Advances in Pharmacology</i> , 2018, 83, 133-154.	1.2	24
56	Implementation of Pharmacogenomics in Everyday Clinical Settings. <i>Advances in Pharmacology</i> , 2018, 83, 219-246.	1.2	33
57	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a033027.	2.9	49
58	Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. <i>Journal of Personalized Medicine</i> , 2019, 9, 40.	1.1	55
59	Evolutionary synthetic minority oversampling technique with random forest for warfarin dose prediction in Chinese patients. , 2019, , .		4
60	Molecular testing for targeted therapies and pharmacogenomics. , 2019, , 349-363.		2
61	ADME pharmacogenetics: future outlook for Russia. <i>Pharmacogenomics</i> , 2019, 20, 847-865.	0.6	12
62	Genetic variants and interactions from a pharmacist-led pharmacogenomics service for PACE. <i>Pharmacogenomics</i> , 2019, 20, 709-718.	0.6	13
63	Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 646-650.	0.7	29
64	Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles. <i>Human Mutation</i> , 2019, 40, e37-e51.	1.1	15
65	Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. <i>Pharmacogenomics</i> , 2019, 20, 1005-1020.	0.6	9
66	<p>Pharmacogenomics In Pharmacy Practice: Current Perspectives</p>. <i>Integrated Pharmacy Research & Practice</i> , 2019, Volume 8, 97-104.	0.9	19
67	Pharmacogenomics. <i>Medical Clinics of North America</i> , 2019, 103, 977-990.	1.1	43
68	Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines. <i>Public Health Genomics</i> , 2019, 22, 16-24.	0.6	9
70	Incorporating Pharmacogenomics in Drug Development. , 2019, , 81-101.		1
71	Translating Pharmacogenomic Research to Therapeutic Potentials. , 2019, , 103-122.		0
72	Pharmacogenetics in Cardiovascular Diseases. , 2019, , 133-179.		3
73	Pharmacogenomics in Latin American Populations. , 2019, , 329-368.		1

#	ARTICLE	IF	CITATIONS
74	The <sc>ACCO</sc>u<sc>NT</sc> Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. <i>Clinical and Translational Science</i> , 2019, 12, 209-217.	1.5	32
75	Non-interventional cardiologistsâ€™ perspectives on the role of pharmacogenomic testing in cardiovascular medicine. <i>Personalized Medicine</i> , 2019, 16, 123-132.	0.8	11
76	Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. <i>Molecular Biology Reports</i> , 2019, 46, 1825-1833.	1.0	11
77	<p>VKORC1 variants as significant predictors of warfarin dose in Emiratis</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 47-57.	0.4	6
78	Warfarin in nonvalvular atrial fibrillationâ€™Time for a change?. <i>Seminars in Dialysis</i> , 2019, 32, 520-526.	0.7	5
79	APOB gene polymorphisms may affect the risk of minor or minimal bleeding complications in patients on warfarin maintaining therapeutic INR. <i>European Journal of Human Genetics</i> , 2019, 27, 1542-1549.	1.4	6
80	Targeted next generation sequencing as a tool for precision medicine. <i>BMC Medical Genomics</i> , 2019, 12, 81.	0.7	54
81	Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?. <i>Cells</i> , 2019, 8, 535.	1.8	27
82	Mind the gap: resources required to receive, process and interpret research-returned whole genome data. <i>Human Genetics</i> , 2019, 138, 691-701.	1.8	10
83	Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users. <i>JAMA Network Open</i> , 2019, 2, e195345.	2.8	95
84	Perioperative management of patients with atrial fibrillation receiving anticoagulant therapy. <i>Journal of Anesthesia</i> , 2019, 33, 551-561.	0.7	4
85	Genetic polymorphisms and dosing of vitamin K antagonist in Indian patients after heart valve surgery. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 35, 539-547.	0.2	0
86	Recommendations for Clinical CYP2C9 Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 746-755.	1.2	84
87	Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. <i>Scientific Reports</i> , 2019, 9, 7323.	1.6	14
88	Pharmacogenomics guidelines: Current status and future development. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 689-693.	0.9	19
89	Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics. <i>Pharmacogenomics</i> , 2019, 20, 599-608.	0.6	4
90	The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 338-349.	2.3	31
92	Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. <i>BMC Medicine</i> , 2019, 17, 76.	2.3	34

#	ARTICLE	IF	CITATIONS
93	Anticoagulation Management With Coumarinic Drugs in Chilean Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983434.	0.7	3
94	The Genetics of Warfarin Doseâ€“Response Variability in Africans: An Expert Perspective on Past, Present, and Future. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 152-166.	1.0	10
95	Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 387-397.	0.5	9
96	The Missing Diversity in Human Genetic Studies. <i>Cell</i> , 2019, 177, 26-31.	13.5	838
97	<p>Effect of genetic polymorphisms on Alzheimer’s disease treatment outcomes: an update</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 631-642.	1.3	21
98	Translating Pharmacogenetics and Pharmacogenomics to the Clinic: Progress in Human and Veterinary Medicine. <i>Frontiers in Veterinary Science</i> , 2019, 6, 22.	0.9	12
99	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1077-1089.	1.6	12
100	CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South&EEast and East Asian populations: A systematic review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 508-524.	0.7	48
101	Warfarin dose requirement in patients having severe thrombosis or thrombophilia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1684-1691.	1.1	10
102	Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003731.	0.5	4
103	Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. <i>Genes</i> , 2019, 10, 261.	1.0	13
104	Precision dosing of warfarin: open questions and strategies. <i>Pharmacogenomics Journal</i> , 2019, 19, 219-229.	0.9	17
105	Genome-wide association studies of therapeutic response: addressing the complexities. <i>Pharmacogenomics</i> , 2019, 20, 213-216.	0.6	4
106	Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 209-214.	0.3	3
107	Cases in Precision Medicine: The Role of Pharmacogenetics in Precision Prescribing. <i>Annals of Internal Medicine</i> , 2019, 170, 796.	2.0	8
108	Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.3	6
109	The GenomeAsia 100K Project enables genetic discoveries across Asia. <i>Nature</i> , 2019, 576, 106-111.	13.7	265
110	Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 121-130.	1.0	6

#	ARTICLE	IF	CITATIONS
111	Methodological quality of clinical practice guidelines for genetic testing in children. <i>Medicine (United States)</i> , 2019, 98, e18521.	0.4	7
112	Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 127-135.	0.8	10
113	Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 18-22.	0.7	10
114	Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China. <i>Pediatric Cardiology</i> , 2019, 40, 29-37.	0.6	3
115	An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. <i>Journal of Neural Transmission</i> , 2019, 126, 5-18.	1.4	57
116	Pharmacogenomics research and clinical implementation in Brazil. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 538-549.	1.2	17
117	Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 36-44.	1.0	11
118	An Ensemble Model With Clustering Assumption for Warfarin Dose Prediction in Chinese Patients. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 2642-2654.	3.9	16
119	Predictors of Over-Anticoagulation in Warfarin Users in the UK General Population: A Nested Caseâ€“Control Study in a Primary Health Care Database. <i>Thrombosis and Haemostasis</i> , 2019, 119, 066-076.	1.8	12
120	Conference report: pharmacogenomics in special populations at WCP2018. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 467-475.	1.1	3
121	Pharmacogenomics and Precision Medicine. , 2019, , 437-451.		2
122	Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Buddâ€“Chiari syndrome on warfarin. <i>Hepatology International</i> , 2019, 13, 214-221.	1.9	11
123	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. <i>AAPS Journal</i> , 2019, 21, 17.	2.2	29
124	Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9588-9593.	1.2	3
125	Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1256-1262.	2.3	90
126	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Singleâ€“Patient Data Metaâ€“Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	2.3	23
127	Evolutionary Ensemble Learning Algorithm to Modeling of Warfarin Dose Prediction for Chinese. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 395-406.	3.9	22
129	Pharmacogenetics: The Impact of Genetics on Nutrientâ€“Drug Interactions. , 2020, , 519-524.		0

#	ARTICLE	IF	CITATIONS
130	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>Value in Health</i> , 2020, 23, 61-73.	0.1	30
131	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 171-175.	2.3	207
132	Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. <i>Pharmacogenomics Journal</i> , 2020, 20, 104-113.	0.9	13
133	Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. <i>Pharmacogenomics Journal</i> , 2020, 20, 126-135.	0.9	14
134	Siponimod and CYP2C9 Allele Prevalence Among Blacks. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 429-431.	1.0	5
135	CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2020, 20, 306-319.	0.9	12
136	Gene-based anticoagulation regimens for an infant after mitral-valve replacement. <i>Medicine (United States)</i> , 2020, 99, 1000000.	0.4	0
137	Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. <i>Pharmacotherapy</i> , 2020, 40, 142-152.	1.2	8
138	Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1-9.	1.5	13
139	Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. <i>International Journal of Legal Medicine</i> , 2020, 134, 433-439.	1.2	7
140	Comparison of the prediction performance of different warfarin dosing algorithms based on Chinese patients. <i>Pharmacogenomics</i> , 2020, 21, 23-32.	0.6	8
141	A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 432-438.	1.0	29
142	Pharmacogenetic Testing: The Ethics of Implementing in Clinical Practice for Chronic Pain Patients. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2020, 34, 69-76.	0.5	0
143	Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study). <i>Pharmacogenomics Journal</i> , 2020, 20, 451-461.	0.9	1
144	Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. <i>Pharmacological Research</i> , 2020, 153, 104590.	3.1	31
145	Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings. <i>Clinical and Translational Science</i> , 2020, 13, 618-627.	1.5	22
146	Pharmacogenomics in kidney transplant recipients and potential for integration into practice. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1457-1465.	0.7	3
147	Pharmacogenomics for Primary Care: An Overview. <i>Genes</i> , 2020, 11, 1337.	1.0	30

#	ARTICLE	IF	CITATIONS
148	<p></p>Influence of PSRC1, CELSR2, and SORT1 Gene Polymorphisms on the Variability of Warfarin Dosage and Susceptibility to Cardiovascular Disease<p></p>. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 619-632.	0.4	7
149	The effects of <i>CYP2C9</i> and <i>VKORC1</i> gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients. Future Cardiology, 2020, 16, 645-654.	0.5	2
150	Clinically relevant endothelial nitric oxide synthase polymorphisms and their impact on drug response. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 927-951.	1.5	15
151	Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2020, 34, 651-662.	1.7	4
152	Pharmacogenetic-Guided Algorithm to Improve Daily Dose of Warfarin in Elder Han-Chinese Population. Frontiers in Pharmacology, 2020, 11, 1014.	1.6	3
153	DBCSMOTe: a clustering-based oversampling technique for data-imbalanced warfarin dose prediction. BMC Medical Genomics, 2020, 13, 152.	0.7	7
154	Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR. BMJ Open, 2020, 10, e032624.	0.8	1
155	Editorial: Pharmacogenetics Research and Clinical Applications: An International Landscape of the Accomplishments, Challenges, and Opportunities. Frontiers in Pharmacology, 2020, 11, 1217.	1.6	5
156	Leveraging genetic ancestry to study health disparities. American Journal of Physical Anthropology, 2021, 175, 363-375.	2.1	29
157	Effects of rare <i>CYP2C9</i> alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation. Pharmacogenomics, 2020, 21, 1021-1031.	0.6	4
158	Optimising Seniorsâ€™ Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drugâ€™Drugâ€™Gene Interactions. Journal of Personalized Medicine, 2020, 10, 84.	1.1	4
159	The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi Warfarin Pharmacogenetic (SWAP) cohort. Scientific Reports, 2020, 10, 11613.	1.6	9
160	Variation in 100 relevant pharmacogenes among emiratis with insights from understudied populations. Scientific Reports, 2020, 10, 21310.	1.6	14
161	Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. Pharmaceutics, 2020, 12, 1240.	2.0	20
162	Variant discovery using next-generation sequencing and its future role in pharmacogenetics. Pharmacogenomics, 2020, 21, 471-486.	0.6	9
163	Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. Pharmacogenomics, 2020, 21, 431-441.	0.6	7
164	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	1.2	39
165	Biomedical Data Science and Informatics Challenges to Implementing Pharmacogenomics with Electronic Health Records. Annual Review of Biomedical Data Science, 2020, 3, 289-314.	2.8	10

#	ARTICLE	IF	CITATIONS
166	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. <i>Thrombosis Research</i> , 2020, 192, 12-20.	0.8	12
167	Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1418-1426.	1.1	21
168	Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?—Results from the ADRED Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1801.	1.0	8
169	Genotype-Guided Dosing of Warfarin in Chinese Adults. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002602.	1.6	13
170	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for <i>CYP2C9</i> and Nonsteroidal Anti-inflammatory Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 191-200.	2.3	195
171	An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 319-332.	1.5	18
172	Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1057-1066.	1.2	5
173	Genotype-guided warfarin therapy: Still of only questionable value two decades on. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 547-560.	0.7	9
174	Warfarin pharmacogenetics in patients with heart valve replacement. <i>Gene Reports</i> , 2020, 20, 100769.	0.4	0
175	Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting. <i>Frontiers in Pharmacology</i> , 2019, 10, 1527.	1.6	10
176	Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. <i>Clinical and Translational Science</i> , 2020, 13, 861-870.	1.5	42
177	Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 305-312.	0.2	8
178	Evaluation of a multimedia marketing campaign to engage African American patients in glaucoma screening. <i>Preventive Medicine Reports</i> , 2020, 17, 101057.	0.8	6
179	Genetic considerations for adults with congenital heart disease. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2020, 184, 149-153.	0.7	7
180	Effects of <i>CYP2C19</i> *2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020, 21, 111-123.	0.6	3
182	Prioritizing rs7294 as a mirSNP contributing to warfarin dosing variability. <i>Pharmacogenomics</i> , 2020, 21, 257-267.	0.6	4
183	Evaluation of clinical impact of pharmacogenomics knowledge involved in CPIC guidelines on Chinese pediatric patients. <i>Pharmacogenomics</i> , 2020, 21, 209-219.	0.6	5
184	Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. <i>Pharmacogenomics</i> , 2020, 21, 141-156.	0.6	39

#	ARTICLE	IF	CITATIONS
185	CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 687-694.	0.9	8
186	The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals. <i>Cell Research</i> , 2020, 30, 717-731.	5.7	165
187	Effect of SAME-TT2R2 score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 659-666.	1.0	2
188	A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 325.	1.6	10
189	Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics. <i>Clinical and Translational Science</i> , 2020, 13, 941-949.	1.5	13
191	Discovery of novel hepatocyte eQTLs in African Americans. <i>PLoS Genetics</i> , 2020, 16, e1008662.	1.5	21
192	The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. <i>Pharmacogenomics</i> , 2020, 21, 559-569.	0.6	24
193	Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090915.	0.7	5
194	Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 643-650.	0.8	11
195	Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms. <i>Pharmacotherapy</i> , 2021, 41, 265-276.	1.2	8
196	Implications of Polymorphisms in the BCKDK and GATA4 Gene Regions on Stable Warfarin Dose in African Americans. <i>Clinical and Translational Science</i> , 2021, 14, 492-496.	1.5	0
197	Warfarin dosing algorithms: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1717-1729.	1.1	43
198	The need of a multicomponent guiding approach to personalize clopidogrel treatment. <i>Pharmacogenomics Journal</i> , 2021, 21, 116-127.	0.9	8
199	Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. <i>Clinical and Translational Science</i> , 2021, 14, 268-276.	1.5	7
200	Genetic Polymorphism Effect on Warfarin-Rifampin Interaction: A Case Report and Review of Literature. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 149-156.	0.4	3
201	Estimating the potential impact of implementing preemptive pharmacogenetic testing in primary care across the UK. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2907-2925.	1.1	17
202	Comprehensive analysis of important pharmacogenes in Koreans using the DMET platform. <i>Translational and Clinical Pharmacology</i> , 2021, 29, 135.	0.3	3
203	Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?. <i>Transplantation Direct</i> , 2021, 7, e650.	0.8	8

#	ARTICLE	IF	CITATIONS
204	Translational biotechnology: A transition from basic biology to evidence-based research. , 2021, , 3-24.		2
205	Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPgX Guidelines. <i>Frontiers in Pharmacology</i> , 2020, 11, 595219.	1.6	103
206	Pharmacogenomics: Basis and Milestones. , 2021, , 1-10.		1
207	Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient. <i>Frontiers in Pharmacology</i> , 2021, 12, 619339.	1.6	1
208	Opportunity for Genotype-€ Guided Prescribing Among Adult Patients in 11 US Health Systems. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 179-188.	2.3	35
209	Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals. <i>Journal of Personalized Medicine</i> , 2021, 11, 94.	1.1	7
210	For better drugs, diversify clinical trials. <i>Science</i> , 2021, 371, 570-571.	6.0	3
211	Synthesis of major pharmacogenomics pretest counseling themes: a multisite comparison. <i>Pharmacogenomics</i> , 2021, 22, 165-176.	0.6	7
212	Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events. <i>Drug Safety</i> , 2021, 44, 601-607.	1.4	6
213	The Interface of Therapeutics and Genomics in Cardiovascular Medicine. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 663-676.	1.3	8
214	In Vivo Functional Effects of <i>CYP2C9 M1L</i>, a Novel and Common Variant in the Yup€™ik Alaska Native Population. <i>Drug Metabolism and Disposition</i> , 2021, 49, 345-352.	1.7	5
215	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
216	Anatomical distribution and expression of <sc>CYP</sc> in humans: Neuropharmacological implications. <i>Drug Development Research</i> , 2021, 82, 628-667.	1.4	11
217	Analysis of Pharmacogenetic Information in Korea Drug Labels. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 21-26.	0.0	0
218	Access to precision medicine in Thailand: a comparative study. <i>Journal of Health Research</i> , 2022, 36, 275-288.	0.4	1
219	Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland. <i>Clinical Epidemiology</i> , 2021, Volume 13, 183-195.	1.5	9
220	Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease. <i>International Journal of General Medicine</i> , 2021, Volume 14, 1093-1100.	0.8	3
221	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. <i>New England Journal of Medicine</i> , 2021, 384, 973-976.	13.9	0

#	ARTICLE	IF	CITATIONS
222	Conceptualization of population-specific human functional immune-genomics projects to identify factors that contribute to variability in immune and infectious diseases. <i>Heliyon</i> , 2021, 7, e06755.	1.4	3
223	Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. <i>Pharmacological Reports</i> , 2021, 73, 1405-1417.	1.5	10
224	Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. <i>JCO Precision Oncology</i> , 2021, 5, 884-895.	1.5	21
225	Pharmacogenetics to guide cardiovascular drug therapy. <i>Nature Reviews Cardiology</i> , 2021, 18, 649-665.	6.1	49
226	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4546-4548.	1.1	4
227	Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting. <i>JAMA Network Open</i> , 2021, 4, e2110446.	2.8	22
228	Evaluation of population-level pharmacogenetic actionability in Alabama. <i>Clinical and Translational Science</i> , 2021, 14, 2327-2338.	1.5	4
229	Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population. <i>Scientific Reports</i> , 2021, 11, 12343.	1.6	16
230	Comprehensive Allele Genotyping in Critical Pharmacogenes Reduces Residual Clinical Risk in Diverse Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 759-767.	2.3	4
231	Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2021, 72, 129-134.	0.4	3
232	Admixture Has Shaped Romani Genetic Diversity in Clinically Relevant Variants. <i>Frontiers in Genetics</i> , 2021, 12, 683880.	1.1	6
233	Pharmacogenetic determinants of warfarin in the Indian population. <i>Pharmacological Reports</i> , 2021, 73, 1396-1404.	1.5	5
234	Personalized medicine in cardiovascular disease: review of literature. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021, 20, 1793-1805.	0.8	8
235	Frequencies of polymorphisms in genes affecting the pharmacokinetics of warfarin in the Zaporizhzhia region. <i>Zaporozhskij Medicinskij Ažurnal</i> , 2021, 23, 476-479.	0.0	0
236	Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-conscious Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 909-925.	2.3	19
237	PharmVar GeneFocus: <i>CYP2C9</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 662-676.	2.3	34
238	Genomewide Association Studies in Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 637-648.	2.3	38
240	Pharmacogenomic Clinical Decision Support: A Review, How to Guide, and Future Vision. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 44-57.	2.3	25

#	ARTICLE	IF	CITATIONS
241	To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 43-51.	0.8	3
242	Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 735-755.	1.6	3
243	Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 952-958.	1.2	9
244	Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs. <i>Diseases (Basel)</i> , 2021, 11, 1078-1083.	1.0	3
245	Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. <i>Scientific Reports</i> , 2021, 11, 17081.	1.6	6
246	Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. <i>Genetics in Medicine</i> , 2021, 23, 2404-2414.	1.1	14
247	Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial. <i>Clinical and Translational Science</i> , 2021, 14, 2532-2543.	1.5	9
248	Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting. <i>Frontiers in Psychiatry</i> , 2021, 12, 724170.	1.3	14
249	Measuring Pharmacogene Variant Function at Scale Using Multiplexed Assays. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 531-550.	4.2	9
250	Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs. <i>Frontiers in Pharmacology</i> , 2021, 12, 648262.	1.6	0
251	The Gene-Drug Duality: Exploring the Pharmacogenomics of Indigenous Populations. <i>Frontiers in Genetics</i> , 2021, 12, 687116.	1.1	3
252	Análisis farmacogenético retrospectivo de una paciente pediátrica en tratamiento anticoagulante: caso clínico. <i>Biomedica</i> , 2021, 41, 403-408.	0.3	1
253	Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). <i>PLoS ONE</i> , 2021, 16, e0251665.	1.1	7
254	Molecular genetic methods in biomedical research. Part III: human gene diagnostics in clinical practice. <i>Fundamental and Clinical Medicine</i> , 2021, 6, 100-109.	0.1	0
255	Stroke Genetics: Turning Discoveries into Clinical Applications. <i>Stroke</i> , 2021, 52, 2974-2982.	1.0	9
256	Catalyzing clinical implementation of pharmacogenomics and personalized medicine interventions in Africa. <i>Pharmacogenomics</i> , 2021, 22, 115-122.	0.6	2
257	Evolutionary synthetic oversampling technique and cocktail ensemble model for warfarin dose prediction with imbalanced data. <i>Neural Computing and Applications</i> , 2021, 33, 11203-11221.	3.2	5
258	Sources of Interindividual Variability. <i>Methods in Molecular Biology</i> , 2021, 2342, 481-550.	0.4	7

#	ARTICLE	IF	CITATIONS
259	Pharmacogenomics: Challenges and Future Perspectives. , 2021, , 1-8.		1
260	Introduction to Precision Medicine: Minority Populations and Cardiovascular Health. Contemporary Cardiology, 2021, , 13-22.	0.0	0
261	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Network Open, 2020, 3, e2029411.	2.8	34
262	Oral Anticoagulants and Precision Medicine: Something Old, Something New. Clinical Pharmacology and Therapeutics, 2020, 107, 1273-1277.	2.3	5
263	Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada. Pharmacogenetics and Genomics, 2021, 31, 29-39.	0.7	8
264	Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk—A Prospective Cohort Study (PENDULUM mono Study) . Circulation Journal, 2020, 85, 27-36.	0.7	14
265	Assessment of primary care practitioners' attitudes and interest in pharmacogenomic testing. Pharmacogenomics, 2020, 21, 1085-1094.	0.6	24
266	Effect of <i>CYP2C9</i> *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response. Pharmacogenomics, 2020, 21, 1271-1277.	0.6	2
268	Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croatian Medical Journal, 2019, 60, 212-220.	0.2	10
269	Use of pharmacogenomics in elderly patients treated for cardiovascular diseases. Croatian Medical Journal, 2020, 61, 147-158.	0.2	4
270	Pharmacogenomics and Rheumatological Practice. Journal of Clinical Rheumatology and Immunology, 0, , 1-12.	0.4	0
271	Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)—“Never Change a Running System?”. Pharmaceuticals, 2021, 14, 1056.	1.7	0
272	Nine-gene pharmacogenomics profile service: The Mayo Clinic experience. Pharmacogenomics Journal, 2021, , .	0.9	13
273	Association between time to therapeutic INR and length of stay following mechanical heart valve surgery. Journal of Cardiac Surgery, 2022, 37, 62-69.	0.3	2
274	Venous Thromboembolism (VTE). , 2017, , .		0
277	Genotype-guided warfarin dosing. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-20.	0.0	0
279	Personalized antiplatelet and anticoagulation therapy: Pharmacogenomics. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 850-855.	0.1	0
280	Generalizable Architectures and Principles of Informatics for Scalable Personalized and Precision Medicine (PPM) Decision Support. Computers in Health Care, 2020, , 277-303.	0.2	0

#	ARTICLE	IF	CITATIONS
281	Ambiguous pharmacogenetic genotyping results in a patient with bone marrow transplantation. <i>Journal of Laboratory Medicine</i> , 2019, 43, 283-286.	1.1	1
282	Effect of Teaching Program on Nurses' Performance Regarding Drugs that Affect Blood Coagulation in Coronary Care Unit. <i>Assiut Scientific Nursing Journal</i> , 2019, 7, 26-36.	0.0	2
283	Pharmacogenomics in Perioperative Care. , 2020, , 117-127.		0
284	Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds. <i>European Cardiology Review</i> , 2020, 15, e53.	0.7	0
285	Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
286	Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans. <i>Frontiers in Pharmacology</i> , 2021, 12, 749786.	1.6	10
287	The Temple Grandin Genome: Comprehensive Analysis in a Scientist with High-Functioning Autism. <i>Journal of Personalized Medicine</i> , 2021, 11, 21.	1.1	5
288	CYP2C9, CYP4F2, VKORC1 Gene Polymorphism in Buryat Population. <i>Russian Journal of Genetics</i> , 2020, 56, 1496-1503.	0.2	4
289	Biochip-based approach for comprehensive pharmacogenetic testing. <i>Drug Metabolism and Personalized Therapy</i> , 2021, 36, 33-40.	0.3	3
290	Cartographic atlas of frequency variation for 45 pharmacogenetic markers in populations of Russia and its neighbor states. <i>Bulletin of Russian State Medical University</i> , 2020, , .	0.3	7
291	Clinical pharmacogenetics. , 2022, , 189-212.		0
292	Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. , 2020, , .		0
293	Anticoagulants and Antiplatelet Drugs. , 2021, , .		0
294	Chapter 27: Pharmacogenomics Testing. , 2020, , .		0
295	Pharmacogenomics of Antithrombotic Drugs. , 2020, , 137-153.		0
296	Genetic Disorders. , 2020, , 1-15.		0
298	Chapter 29: Pharmacogenomics and Secondary/Incidental Findings. , 2020, , .		0
299	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
300	Current situations of and how to deal with polypharmacy in non-valvular atrial fibrillation. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 591-598.	0.1	0
301	The United States 2020 Census data: implications for precision medicine and the research landscape. Personalized Medicine, 2022, 19, 5-8.	0.8	15
302	Farmacogenômica e Doença Cardiovascular: Onde Estamos e Para Onde Vamos. Arquivos Brasileiros De Cardiologia, 2020, 115, 690-700.	0.3	0
304	Voriconazole-warfarin interaction necessitating warfarin dose management in an invasive aspergillosis patient: A case report. Clinical & Experimental Thrombosis and Hemostasis, 2020, 6, 12-15.	0.2	0
305	Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico. Puerto Rico Health Sciences Journal, 2017, 36, 165-172.	0.2	1
306	PRECISION MEDICINE: FROM DIPLYPES TO DISPARITIES TOWARDS IMPROVED HEALTH AND THERAPIES. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 389-399.	0.7	1
308	Translating Pharmacogenomic Research to Therapeutic Potentials (Bench to Bedside). , 2021, , .		0
309	Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?. Journal of Personalized Medicine, 2021, 11, 1180.	1.1	4
310	Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. Cardiology Research and Practice, 2021, 2021, 1-8.	0.5	0
311	Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations. Journal of Personalized Medicine, 2021, 11, 1226.	1.1	3
312	Pharmacogenomic analysis of a genetically distinct Indigenous population. Pharmacogenomics Journal, 2021, , .	0.9	4
313	Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A Systematic and Critical Review of Economic Evaluations. Value in Health, 2022, 25, 461-472.	0.1	1
314	Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program. Journal of Personalized Medicine, 2022, 12, 161.	1.1	2
315	The efficacy of low-dose warfarin initiation (3 mg versus 5 mg) in newly diagnosed venous thromboembolism patients among a population with a high prevalence of warfarin-sensitive haplotype of the VKORC1 gene: a randomized controlled trial. Hematology, 2022, 27, 95-104.	0.7	3
316	The VKORC1 and CYP2C9 gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients - consideration of hypersensitivity and resistance. Srpski Arhiv Za Celokupno Lekarstvo, 2022, 150, 156-162.	0.1	0
317	Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population. PLoS ONE, 2022, 17, e0263137.	1.1	10
318	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. British Journal of Clinical Pharmacology, 2022, , .	1.1	3
319	Genetic Disorders. , 2022, , 207-221.		0

#	ARTICLE	IF	CITATIONS
320	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1007-1021.	2.3	120
321	The pharmacist's responsibility to ensure appropriate use of direct-to-consumer genetic testing. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 652-658.	0.5	4
322	Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data. <i>Npj Genomic Medicine</i> , 2022, 7, 12.	1.7	10
323	Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100312.	1.5	9
324	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	1.6	17
325	A population study of clinically actionable genetic variation affecting drug response from the Middle East. <i>Npj Genomic Medicine</i> , 2022, 7, 10.	1.7	20
326	The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping. <i>Frontiers in Pharmacology</i> , 2022, 13, 867331.	1.6	4
327	A novel, rapid and simple UHPLC-MS/MS method for quantification of warfarin in dried blood spots. <i>Analytical Biochemistry</i> , 2022, , 114664.	1.1	0
328	Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 599-607.	1.0	8
329	Exploring the Kinh Vietnamese genomic database for the polymorphisms of the P450 genes towards precision public health. <i>Annals of Human Biology</i> , 2022, 49, 152-155.	0.4	0
330	Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting. <i>Indian Heart Journal</i> , 2022, , .	0.2	2
331	Ethnic Diversity and Warfarin Pharmacogenomics. <i>Frontiers in Pharmacology</i> , 2022, 13, 866058.	1.6	17
332	Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. <i>Pharmacogenomics Journal</i> , 2022, 22, 188-197.	0.9	4
333	Association of <i>VKORC1</i> and <i>CYP2C9</i> single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. <i>Drug Metabolism and Personalized Therapy</i> , 2022, .	0.3	0
334	Direct Oral Anticoagulants (DOAC): Are We Ready for a Pharmacogenetic Approach?. <i>Journal of Personalized Medicine</i> , 2022, 12, 17.	1.1	3
335	The Landscape of Clinical Implementation of Pharmacogenetic Testing in Central China: A Single-Center Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1619-1628.	0.4	2
336	Current and future state of clinical pharmacist-led precision medicine initiatives. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 754-764.	0.5	3
337	Genetic Risk Factors for Adverse Drug Reactions. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 48-64.	0.1	3

#	ARTICLE	IF	CITATIONS
338	The Impact of <i>CYP2C9*11</i> Allelic Variant on the Pharmacokinetics of Phenytoin and Warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 156-163.	2.3	5
339	Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	1
340	Pharmacists closing health disparity gaps through pharmacogenomics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0
341	Long Short-Term Memory Network for Development and Simulation of Warfarin Dosing Model Based on Time Series Anticoagulant Data. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	0
342	Frequency of CYP2C9 Promoter Variable Number Tandem Repeat Polymorphism in a Spanish Population: Linkage Disequilibrium with CYP2C9*3 Allele. <i>Journal of Personalized Medicine</i> , 2022, 12, 782.	1.1	0
343	Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease. <i>Advances in Pharmacology</i> , 2022, , 141-182.	1.2	0
344	Pharmacogenetic variants influence vitamin K anticoagulant dosing in patients with mechanical prosthetic heart valves. <i>Pharmacogenomics</i> , 2022, 23, 475-485.	0.6	1
345	Pharmacogenomics: Challenges and Future Perspectives. , 2022, , 883-890.		0
346	Advancing equity in the promise of pharmacogenomics. , 2022, , 85-106.		1
347	Pharmacogenomics: Basis and Milestones. , 2022, , 874-883.		0
348	Clinical considerations for precision medicine clinical decision support. , 2022, , 175-200.		1
349	Pharmacogenomic Profile of Amazonian Amerindians. <i>Journal of Personalized Medicine</i> , 2022, 12, 952.	1.1	1
351	A new chiral stationary phase based on noscapine: Synthesis, enantioseparation, and docking study. <i>Chirality</i> , 0, , .	1.3	1
352	Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant – implications for precision dosing in a global perspective. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5149-5165.	1.1	4
353	Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects. <i>Advances in Pharmacology</i> , 2022, , 49-72.	1.2	0
354	A clinician’s guide for counseling patients on results of a multigene pharmacogenomic panel. <i>American Journal of Health-System Pharmacy</i> , 0, , .	0.5	1
355	How to implement a pharmacogenetics service at your institution. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 1161-1175.	0.5	2
357	The role of <i>CYP2C19</i> genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 811-825.	1.3	6

#	ARTICLE	IF	CITATIONS
358	Drug metabolism and drug transport of the 100 most prescribed oral drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 131, 311-324.	1.2	28
359	Pharmacogenomics Informs Cardiovascular Pharmacotherapy. <i>Methods in Molecular Biology</i> , 2022, , 201-240.	0.4	0
360	Chapter 9: Cardiology: Warfarin/<i>CYP2C9</i>, <i>VKORC1</i>, <i>CYP4F2</i> Case. , 2022, , .		0
361	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. , 2022, , .		0
362	Chapter 3: Pharmacogenomics Testing. , 2022, , .		0
363	Chapter 2: Pharmacogenomics: Drug Exposure and Response. , 2022, , .		0
364	Effect of CYP2C9*2 and VKORC-1639G/A Polymorphisms on Warfarin Doses Requirements in Sudanese Patients. <i>International Journal of Pharmacology</i> , 2022, 18, 1366-1373.	0.1	0
365	Opposite Response to Vitamin K Antagonists: A Report of Two Cases and Systematic Review of Literature. <i>Journal of Personalized Medicine</i> , 2022, 12, 1578.	1.1	1
366	Impact of ABCB1 C3435T Polymorphism on Treatment Response of Vitamin K Antagonists: A Systematic Review and Meta-analysis. <i>Korean Journal of Clinical Pharmacy</i> , 2022, 32, 238-250.	0.0	0
367	Genetic Variation among Pharmacogenes in the Sardinian Population. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10058.	1.8	1
368	Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. <i>Human Genomics</i> , 2022, 16, .	1.4	2
369	Recommendations for Clinical Application of Pharmacogenetic Test Results Interpretation by Clinical Laboratories. <i>Laboratory Medicine Online</i> , 2022, 12, 244-261.	0.0	0
370	Genome Reporting for Healthy Populationsâ€™ Pipeline for Genomic Screening from the GENCOV COVIDâ€™19 Study. <i>Current Protocols</i> , 2022, 2, .	1.3	2
371	Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites. , 2022, , 197-232.		0
372	Barriers to genetic testing in clinical psychiatry and ways to overcome them: from cliniciansâ€™ attitudes to sociocultural differences between patients across the globe. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	8
373	Hemostatic Agents for the Management of Bleeding Risk Associated with Oral Anticoagulant Therapy Following Tooth Extraction: A Systematic Review. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 11017.	1.3	2
374	Diversity of pharmacogenomic variants affecting warfarin metabolism in Sri Lankans. <i>Pharmacogenomics</i> , 0, , .	0.6	0
375	Local Ancestryâ€™Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 680-691.	2.3	0

#	ARTICLE	IF	CITATIONS
376	Drug-Drug Gene Interactions in Cardiovascular Medicine. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 15, 879-911.	0.4	3
377	Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art. <i>Stroke</i> , 2023, 54, 270-278.	1.0	7
378	Pharmacogenetics of siponimod: A systematic review by Díaz-Villamarín et al. "Information is power. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114003.	2.5	2
379	Implementation of pharmacogenomics: Where are we now?. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	6
380	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 533-546.	0.7	3
381	Optimizing warfarin dosing using deep reinforcement learning. <i>Journal of Biomedical Informatics</i> , 2023, 137, 104267.	2.5	6
382	Association of <i>VKORC1</i> and <i>CYP2C9</i> single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. <i>Drug Metabolism and Personalized Therapy</i> , 2022, 37, 353-359.	0.3	2
383	Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?. <i>Expert Review of Respiratory Medicine</i> , 0, , 1-8.	1.0	1
384	Clinical significance of the series of <i>CYP2C9</i> *non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
385	A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 518-527.	2.3	5
387	Pharmacogenomic variabilities in geo-ancestral subpopulations and their clinical implications: Results of collaborations with Hmong in the United States. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
388	Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs. <i>Current Cardiovascular Risk Reports</i> , 2023, 17, 27-38.	0.8	1
389	Is there still room for warfarin after the appearance of direct oral anticoagulants?. <i>Atherothrombosis</i> , 2023, 12, 32-42.	0.1	1
390	Automated warfarin dose prediction for Asian, American, and Caucasian populations using a deep neural network. <i>Computers in Biology and Medicine</i> , 2023, 153, 106548.	3.9	5
391	PAnno: A pharmacogenomics annotation tool for clinical genomic testing. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
392	Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	0
393	Pharmacogenomics and health disparities, are we helping?. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	2
394	Exploring the potential benefits of pharmacogenomics in chronic respiratory diseases. <i>Pharmacogenomics</i> , 2023, 24, 239-241.	0.6	0

#	ARTICLE	IF	CITATIONS
395	Pharmacogenomics in Asians: Differences and similarities with other human populations. Expert Opinion on Drug Metabolism and Toxicology, 2023, 19, 27-41.	1.5	11
396	A method for an unbiased estimate of cross-ancestry genetic correlation using individual-level data. Nature Communications, 2023, 14, .	5.8	4
397	A genome-wide CRISPR-Cas9 knockout screen identifies FSP1 as the warfarin-resistant vitamin K reductase. Nature Communications, 2023, 14, .	5.8	22
398	<scp>Warfarinâ€Rifampinâ€Gene</scp> (WARIFâ€G) Interaction: AÂRetrospective, Genetic, <scp>Caseâ€Control</scp> Study. Clinical Pharmacology and Therapeutics, 2023, 113, 1150-1159.	2.3	1
399	What Is Precision Medicine?. Physician Assistant Clinics, 2023, 8, 371-390.	0.1	0
400	The prevalence of pharmacogenetic variants of vitamin K epoxide reductase complex subunit 1 gene (rs9923231), cytochrome P450 family 2 subfamily C member 9 gene (rs1799853) and cytochrome P450 family 3 subfamily-A member-5 gene (rs776746) among 13 ethnic groups of Pakistan. Molecular Biology Reports, 0, .	1.0	0
401	Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Human Genomics, 2023, 17, .	1.4	11
402	A national survey of individualized pharmaceutical care practice in Chinese hospitals in 2019. Frontiers in Pharmacology, 0, 14, .	1.6	1
403	Deriving mechanismâ€based pharmacodynamic models by reducing quantitative systems pharmacology models: An application to warfarin. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 432-443.	1.3	4
404	A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China. Journal of Clinical Laboratory Analysis, 2023, 37, .	0.9	6
405	Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects. Frontiers in Endocrinology, 0, 14, .	1.5	1
406	Evolutionary Genetics and Admixture in African Populations. Genome Biology and Evolution, 2023, 15, .	1.1	7
407	Developing Chinese race-specific warfarin dose prediction algorithms. International Journal of Clinical Pharmacy, 0, , .	1.0	0
408	Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population. Drug Metabolism and Personalized Therapy, 2023, .	0.3	2
409	Cannabis Pharmacogenomics: A Path to Personalized Medicine. Current Issues in Molecular Biology, 2023, 45, 3479-3514.	1.0	2
410	Pharmacogenetics and toxicology. , 2024, , 467-491.		0
415	Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies. Clinical Pharmacokinetics, 2023, 62, 819-833.	1.6	0
417	Engaging diversity in research: does your drug work in overlooked populations?. , 2023, , 283-292.		0

#	ARTICLE	IF	CITATIONS
418	Genetic Contributions and Personalized Medicine. , 2023, , 3-17.		0
419	Trends and implementation of preemptive pharmacogenomic testing. , 2024, , 363-381.		0
420	Pharmacogenomics and diabetes. , 2023, , 115-135.		0
429	Pharmacogenetics and Pharmacogenomics in Precision Medicine. , 2023, , 151-162.		0
440	Pocket cardiology. , 2024, , 436-442.		0
448	Molecular diagnostics for coagulopathies. , 2024, , 241-253.		0
456	Pharmacogenomics of Cardiovascular Diseases: The Path to Precision Therapy. , 0, , .		0
460	Pharmacogenomics in Drug Metabolism Enzymes and Transporters. , 2023, , 1-47.		0
464	Pharmacogenomics in Cardiovascular Diseases. , 2023, , 201-237.		0
465	An Overview of Personalized Medicine Development Through Recent Advances in Genome-Wide Association Studies. IFMBE Proceedings, 2024, , 261-274.	0.2	0
466	Clinical Genetics and Referrals. , 2024, , 45-72.		0
467	Pharmacogenomics of Drug-Metabolizing Enzymes. , 2023, , 35-60.		0
468	Pharmacogenomics of Drug Safety. , 2023, , 413-437.		0
469	Pharmacogenetic Algorithms. , 2023, , 105-131.		0
470	Pharmacogenomic Cases: Warfarin for Atrial Fibrillation. , 2024, , 499-501.		0